Seven hub genes that may play a role in SSc pathways and development were identified including THY1 and SULF1 as prognostic markers.18 Ten small-molecule drugs with potential therapeutic effects were also identified, mainly including phosphodiesterase inhibitors (BRL-50481, dipyridamole) and transforming growth factor beta (TGF-β) receptor inhibitors (SB-525334).18 Here, THY1 is linked to systemic sclerosis.